ESTRO 2025 - Abstract Book

S2013

Clinical - Urology

ESTRO 2025

Kieran Palmer, Muhammad Rauf, James Barber, Hannah Powell, Alex Putney, Adam Mitchell, Sonia Mansukhani, Amy Clifford, Mark Prentice, Sarah Needleman Oncology Department, Royal Free Hospital, London, United Kingdom Purpose/Objective: Health inequalities are known to influence prostate cancer morbidity and mortality. Here, we aimed to assess the effect of age, relative socio-economic deprivation, ethnicity, language and fitness on the enrolment into prostate cancer radiotherapy clinical trials. Material/Methods: Retrospective analysis of patients with non-metastatic prostate cancer treated with radical radiotherapy between February 2017 and August 2024 at our centre was performed. Patients treated with prostate bed radiotherapy were excluded. Clinical trials included PACE-B, PACE-C, PACE-NODES, PEARLS and PIVOTALBOOST. Relative socio-economic deprivation was derived from the indices of multiple deprivation (IMD) which is based upon each patient’s post -code. Ethnicity was categorised as per the United Kingdom 2021 Census. Differences in baseline demographics between the trial and non-trial cohorts were assessed using the Mann- Whitney and Fisher’s exact tests. Results: 1083 patients were included; 62 patients were recruited into clinical trials and 1021 patients were treated outside of a trial. Whilst there were no statistically significant differences between groups, there was a trend towards underrepresentation of patients of Asian, Asian British or Asian Welsh ethnicity (8.1% vs 10.1%), Black, Black British, Black Welsh, Caribbean or African ethnicity (6.5% vs 10.0%), higher relative income deprivation (income IMD deciles 1-3: 21.0% vs 29.5%), requiring an interpreter (0.0% vs 3.6%) and with reduced performance status (16.1% vs 26.2% performance status 1; 1.6% vs 3.0% performance status 2).

Conclusion: